Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs

Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs

Treatment of chronic hepatitis C is currently based on a combination of pegylated interferon-α and ribavirin. Neither drug exerts direct selective pressure on viral functions, meaning that interferon-α/ribavirin treatment failure is not due to selection of interferon-α- or ribavirin-resistant viral...

Full description

Bibliographic Details
Main Author: Jean-Michel Pawlotsky
Format: Article
Language:English
Published: SAGE Publishing 2009-07-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756283X09336045
id doaj-022477bef2694a3d912b55ace547125c
record_format Article
spelling doaj-022477bef2694a3d912b55ace547125c2020-11-25T03:39:32ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X2009-07-01210.1177/1756283X09336045Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugsJean-Michel PawlotskyTreatment of chronic hepatitis C is currently based on a combination of pegylated interferon-α and ribavirin. Neither drug exerts direct selective pressure on viral functions, meaning that interferon-α/ribavirin treatment failure is not due to selection of interferon-α- or ribavirin-resistant viral variants. Several novel antiviral approaches are currently in preclinical or clinical development, and most target viral enzymes and functions, such as hepatitis C virus protease and polymerase. These new drugs all potentially select resistant viral variants both in vitro and in vivo, and resistance is therefore likely to become an important issue in clinical practice.https://doi.org/10.1177/1756283X09336045
collection DOAJ
language English
format Article
sources DOAJ
author Jean-Michel Pawlotsky
spellingShingle Jean-Michel Pawlotsky
Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
Therapeutic Advances in Gastroenterology
author_facet Jean-Michel Pawlotsky
author_sort Jean-Michel Pawlotsky
title Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
title_short Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
title_full Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
title_fullStr Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
title_full_unstemmed Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
title_sort review: therapeutic implications of hepatitis c virus resistance to antiviral drugs
publisher SAGE Publishing
series Therapeutic Advances in Gastroenterology
issn 1756-283X
publishDate 2009-07-01
description Treatment of chronic hepatitis C is currently based on a combination of pegylated interferon-α and ribavirin. Neither drug exerts direct selective pressure on viral functions, meaning that interferon-α/ribavirin treatment failure is not due to selection of interferon-α- or ribavirin-resistant viral variants. Several novel antiviral approaches are currently in preclinical or clinical development, and most target viral enzymes and functions, such as hepatitis C virus protease and polymerase. These new drugs all potentially select resistant viral variants both in vitro and in vivo, and resistance is therefore likely to become an important issue in clinical practice.
url https://doi.org/10.1177/1756283X09336045
work_keys_str_mv AT jeanmichelpawlotsky reviewtherapeuticimplicationsofhepatitiscvirusresistancetoantiviraldrugs
_version_ 1724538181408260096

Similar Items